a b s t r a c t 25B-NBOMe and 25C-NBOMe are potent 5-HT 2A receptor agonists that have been associated with inducing hallucinogenic effects in drug users and severe intoxications. This paper describes the identification of their metabolites in rat and human urine by liquid chromatography (LC)-high resolution (HR)-MS/MS, the comparison of metabolite formation in vitro and in vivo and in different species, the general involvement of human cytochrome-P450 (CYP) isoenzymes on their metabolism steps, and their detectability by standard urine screening approaches (SUSAs) using GC-MS, LC-MS n , or LC-HR-MS/MS. Both NBOMe derivatives were mainly metabolized by O-demethylation, O,O-bis-demethylation, hydroxylation, and combinations as well as by glucuronidation and sulfation of the main phase I metabolites. For 25B-NBOMe, 66 metabolites could be identified and 69 for 25C-NBOMe. After application of low doses of both substances to rats, they were detectable mainly via their metabolites by both LC-based SUSAs. In case of acute intoxication, it was possible to detect 25B-NBOMe and its metabolites in an authentic human urine sample when using the GC-MS SUSA in addition to the LC-based SUSAs. Initial CYP activity screening revealed the involvement of CYP1A2 and CYP3A4 in hydroxylation and CYP2C9 and CYP2C19 in O-demethylation. The presented study demonstrated that 25B-NBOMe and 25C-NBOMe were extensively metabolized and detectable by both LC-based SUSAs.
Introduction
According to annual drug reports published by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and United Nations Office on Drugs and Crime (UNODC) [1] [2] [3] [4] , the availability and abuse of new psychoactive substances (NPS) increased during the last few years. Besides synthetic cannabinoids, cathinones, opioids, and tryptamines, the group of phenethylamines lamines), represent a new group of potent phenethylamine hallucinogens with high abuse potential. 2-(4-Bromo-2,5-dimethoxyphenyl)-N-[(2-methoxy¬phenyl)methyl]ethanamine (25B-NBOMe, 2C-B-NBOMe), 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxy¬phenyl)methyl]ethanamine (25C-NBOMe, 2C-C-NBOMe), and 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 25I-NBOMe, 2C-I-NBOMe) are among the most prevalent NBOMes. They are consumed depending on desired effects in reported dosages between 200 and 1000 g, administered orally, sublingually, bucally or insufflated as powder or in solution as nose spray [8, [13] [14] [15] [16] [17] [18] [19] [20] . In recent years, NBOMe consumption was described in the context of acute and severe intoxications and fatalities [8, [14] [15] [16] [17] [18] 21, 22] . In some cases, an unintentional intake of NBOMes, sold as LSD or 2Cs, were found to be responsible for adverse events [8, 15, 19, 22] . However, 25B-NBOMe has also been employed in positron emission tomography (PET) in human volunteers to assess binding of this ligand in distinct brain areas and at non-psychoactive dosage levels [23, 24] .
Due to high receptor affinity and functional activity as full agonists, comparatively low doses, comparable to LSD, are needed to induce psychoactive effects. Consequently, the resulting low blood plasma or urine concentrations can make it challenging to identify and characterize the intake of NBOMes. In urine, the concentration of compounds is generally higher than in blood, but in many cases, metabolites rather than the parent compounds are the targets. Therefore, metabolism studies are needed for the development of urine screening approaches. The comprehensive metabolism study for 25I-NBOMe revealed that it was extensively metabolized and that the parent compound was found in urine only in small amounts [25] .
Recently, Wohlfarth et al. [26] described the metabolism of 25C-NBOMe and 25I-NBOMe in mice and human urine as well as in human hepatocytes, and the reported results were consistent with previously published human and rat data for 25I-NBOMe [25] . For 25B-NBOMe, only limited data on its biotransformation are available [27, 28] , and for both compounds, no comprehensive data appear to be available on their detectability. Therefore, the aims of the present study were to investigate the metabolism of 25B-NBOMe and 25C-NBOMe in rats and humans with LC-HR-MS/MS, to compare the results with in vitro and in vivo data and between different species, and to investigate their detectability by the authors' standard urine screening approaches (SUSA) by GC-MS, LC-MS n , and LC-HR-MS/MS, respectively.
Experimental

Chemicals and reagents
25B-NBOMe hydrochloride and 25C-NBOMe hydrochloride were purchased by LGC Standards (Wesel, Germany). Isolute HCX cartridges (130 mg, 3 mL) were obtained from Biotage (Uppsala, Sweden), isocitrate and isocitrate dehydrogenase from Sigma (Taufkirchen, Germany), NADP + from Biomol (Hamburg, Germany), acetonitrile (LC-MS grade), ammonium formate (analytical grade), formic acid (LC-MS grade), methanol (LC-MS grade), mixture (100,000 Fishman units/mL) of glucuronidase (EC No. 3.2.1.31) and arylsulfatase (EC No. 3.1.6.1) from Helix Pomatia, and all other chemicals and reagents (analytical grade) from VWR (Darmstadt, Germany). The baculovirus-infected insect cell microsomes (Supersomes) containing 1 nmol/mL of human cDNA-expressed CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 (2 nmol/mL), CYP3A4, or CYP3A5 (2 nmol/mL) were obtained from Corning (Amsterdam, The Netherlands). After delivery, the CYPs were thawed at 37 • C, aliquoted, snap-frozen in liquid nitrogen, and stored at −80 • C until use.
Urine samples
According to an established study design [29] , the investigations were performed using rat urine samples from male Wistar rats (Charles River, Sulzfeld, Germany) for toxicological diagnostic reasons according to German law. Both compounds were administered in an aqueous suspension by gastric intubation of a single 10 mg/kg body weight (BW) dose for identification of the metabolites and of 0.1 mg/kg BW for screening (dose calculated based on common single dose reported in trip reports (https://www.erowid. org) and scaled by dose-by-factor approach from man to rat according to Sharma and McNeill [30] ), respectively. The rats were housed in metabolism cages for 24 h, having water ad libitum. Urine was collected separately from feces over a 24 h period. Blank urine samples were collected before drug administration to verify that the samples were free of interfering compounds. The samples were directly analyzed and then stored at −20 • C.
In addition, for 25B-NBOMe, an authentic ante mortem human urine sample after unintentional intake of an unknown dose of 25B-NBOMe (declared as 2C-B) submitted to the authors' laboratory for toxicological diagnostics was also analyzed.
Sample preparation
Sample preparation for identification of phase I metabolites by LC-HR-MS/MS
According to a published procedure [29] , 2 mL of urine was adjusted to pH 5.2 with acetic acid (1 M, approximately 50 L) and incubated at 50 • C for 2 h with 50 L of a mixture of glucuronidase and arylsulfatase. The urine sample was then loaded on an HCX cartridge previously conditioned with 1 mL of methanol and 1 mL of water. After passage of the sample, the cartridge was washed with 1 mL of water, 1 mL of 0.01 M hydrochloric acid, and again with 1 mL of water. The acidic and neutral compounds were eluted with 1 mL of methanol into a 1.5 mL reaction vial and evaporated to dryness under a stream of nitrogen. In the same reaction vial, the basic compounds were eluted with 1 mL of a freshly prepared mixture of methanol/aqueous ammonia 32% (98:2, v/v). After another evaporation step the residues were reconstituted with 50 L of a mixture of eluent A and B (1:1, v/v) for LC-HR-MS/MS analysis. A 5-L aliquot was then injected onto the LC-HR-MS/MS.
Sample preparation for identification of phase II metabolites by LC-HR-MS/MS
According to a published procedure [29] , 100 L of urine was mixed with 500 L of acetonitrile for precipitation. After shaking and centrifugation, the supernatant was gently evaporated to dryness and reconstituted in 50 L of a mixture of 10 mM aqueous ammonium formate buffer and acetonitrile (1:1, v/v) and 5 L injected onto the LC-HR-MS/MS system.
Incubations for initial CYP activity screening studies
According to standard procedures [29, 31] , microsomal incubations were performed at 37 • C at a concentration of 25 M 25B-NBOMe and 25C-NBOMe, respectively, with the CYP isoenzymes (75 pmol/mL, each) CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, or CYP3A5 for 30 min. Besides enzymes and substrates, the incubation mixtures (final volume, 50 L) contained 90 mM phosphate buffer (pH 7.4), 5 mM Mg 2+ , 5 mM isocitrate, 1.2 mM NADP + , 0.5 U/mL isocitrate dehydrogenase, and 200 U/mL superoxide dismutase. For incubations with CYP2A6 and CYP2C9, phosphate buffer was replaced with 45 mM or 90 mM Tris buffer, respectively, according to the Gentest manual. Reactions were initiated by addition of the CYP enzymes and stopped with 50 L of ice-cold acetonitrile. The solution was centrifuged for 2 min at 14,000 rpm; 70 L of the supernatant phase were transferred to an autosampler vial and 5 L injected onto the LC-HR-MS/MS system.
LC-HR-MS/MS instrumentation for identification of phase I and II metabolites and CYP initial screening
According to a published procedure [32] , the extracts were analyzed using a ThermoFisher Scientific (TF, Dreieich, Germany) Dionex UltiMate 3000 RS pump consisting of a degasser, a quaternary pump, and an UltiMate autosampler, coupled to a TF Q-Exactive Plus system equipped with a heated electrospray ionization (HESI)-II source. The instrument was used in positive or in negative ionization mode. Mass calibration was performed prior to analysis according to the manufacturer's recommendations using external mass calibration.
Gradient elution was run on a TF Accucore PhenylHexyl column (100 mm × 2.1 mm, 2.6 m). The HESI-II source conditions were as follows: sheath gas, 60 arbitrary units (AU); auxiliary gas, 10 AU; spray voltage, 3.00 (positive polarity) and −4.00 kV (negative polarity); heater temperature, 320 • C; ion transfer capillary temperature, 320 • C; and S-lens RF level, 60.0. Mass spectrometry was performed in positive and negative polarity mode using full scan (FS) data and a subsequent data dependent acquisition (DDA) mode with an inclusion list on the masses of interest (phase I or phase II metabolites). Additionally, DDA runs without inclusion list (positive and negative mode) were performed to detect unexpected metabolites.
The settings for FS data acquisition were as follows: resolution, 35,000; microscans, 1; automatic gain control (AGC) target, 1e6; maximum injection time (IT), 120 ms; and scan range, m/z 100-700. The settings for the DDA mode with and without an inclusion list were as follows: resolution, 17,500; microscans 1, AGC target, 2e5; maximum IT, 250 ms; isolation window, 1.0 m/z, HCD with stepped normalized collision energy (NCE), 17.5, 35, and 52.5%; spectrum data type, profile; and underfill ratio, 0.5%. For the run without inclusion list, the five most intense precursor ions were transferred to an exclusion list for 1 s (dynamic exclusion).
For analyzing the initial CYP activity screening, the MS settings and the mobile phases as well as the gradient and flow rate were the same with the same inclusion list as for identification of phase I metabolites.
Standard urine screening procedures (SUSAs)
The SUSAs were performed as described in the following references: GC-MS SUSA [33, 34] , LC-MS n SUSA [25, 35] , and LC-HR-MS/MS SUSA [25, 36] . The HR-MS/MS fragmentation patterns and metabolite formation of 25B-NBOMe and 25C-NBOMe were similar to those described for 25I-NBOMe [25] . Briefly, and for discussion purposes, the molecules were viewed as two distinct parts, i.e. the 4-halogenated 2,5-dimethoxyphenethylamine (2C) part and the N-(2-methoxybenzyl) (NBOMe) part. Due to the high number of metabolites, the fragmentation patterns could not be discussed in detail for all metabolites and only the typical fragment ions used for identification will be discussed.
In general, for both compounds and their metabolites, the precursor masses and the most abundant fragment ions formed from unmodified or modified NBOMe parts were used to identify the corresponding metabolites. As expected, the fragment ions formed by the NBOMe part were identical for 25B-NBOMe and 25C-NBOMe. To confirm the predicted chemical structure of the metabolites, the corresponding 2C fragment ions (Table S1 in the electronic Supplementary data for 25B-NBOMe and Table S2 for 25C-NBOMe) were used. For the N-dealkylated metabolites, no fragment ions of the NBOMe part could be detected, but characteristic 2C fragmentation patterns for the bromo and chloro analogues (Tables S1 and  S2 ). The precursor masses (PM) are given with the calculated exact masses.
25B-NBOMe (B1; PM at m/z 380.0856, M+H + ) showed a fragmentation pattern characteristic also for most of the detected metabolites. The most abundant fragment ion of m/z 121.0653 represented the cleavage of the NBOMe moiety, followed by the loss of the methoxy group (−30.0105 u) producing the tropylium ion of m/z 91.0548. The fragment ions representing the 2C part showed low abundances of at least 1% (Table S1 ). The fragment ion of m/z 258.0124 representing the 2C-B iminium ion resulted from benzyl cleavage. A loss of NH (−15.0109 u) formed the fragment ion of m/z 243.0021 followed by a loss of a methyl radical (−15.0235 u) of one of the two methoxy groups in the 2C part resulting in fragment ion of m/z 227.9786. For the MS 2 spectrum of 25I-NBOMe, a rearrangement was described in the literature [25] . In the parent spectrum of 25B-NBOMe, one fragment ion could also be formed by the same rearrangement. The fragment ion of m/z 363.0596 resulted from a loss of ammonia (-17.0263 u) and appeared consistent with the postulated rearrangement reaction. Few MS 2 spectra of metabolites also showed possible rearranged fragment ions.
The fragmentation patterns of 25C-NBOMe (C1; PM at m/z 336.1361, M + H + ) corresponded to those of 25B-NBOMe and 25I-NBOMe. Similarly, the most abundant fragment ions in MS 2 were formed by cleavage of the NBOMe moiety producing fragment ions of m/z 91.0548 and 121.0653. Also, the fragment ions representing the 2C part showed a lower abundance of about 1% (Table  S2 ). The fragment ions of m/z 214.0629, m/z 199.0526, and m/z 184.0291 represented the 2C-C iminium ion, the subsequent loss of NH (-15.0109 u), and the loss of a methyl radical (-15.0235 u) of one of the two methoxy groups, respectively. In the spectrum of 25C-NBOMe, no fragment ions indicating the rearrangement were detected, possibly due to low relative abundance. However, in the MS 2 spectra of some 25C-NBOMe metabolites (e.g. O-demethyl metabolite isomers 1 and 2, C16 and C17), some rearranged fragment ions could also be detected. Overall, 35 phase I metabolites could be detected for 25B-NBOMe in urine and 36 for 25C-NBOMe, respectively. All phase I metabolites are listed in Tables S1 and S2 in the electronic Supplementary data.
For metabolite identification based on the MS 2 spectra, in most cases the representative fragment ion for the NBOMe part was used. Unmodified NBOMe parts led to a fragment ion of m/z 121.0653. The presence of this fragment ion led to the suggestion that the expected modification took place at the 2C part based on the predicted precursor mass for the metabolite. An unchanged fragment ion of m/z 121.0653 could be seen for the parent compounds (B1 and C1) as well as for mono-and bis-demethylated (B13, B14, B8 and C16, C17, C10), mono-hydroxylated (B29, B32 and C31, C32), bis-hydroxylated (B35), combined mono-demethylated with mono-hydroxylated (B22), dehydrogenated (B20 and C24), dehydrogenated combined with mono-demethylated (B12 and C13), and mono-hydroxylated (B27 and C30) metabolites. On the other hand, the fragment ion of m/z 137.0603 represented monohydroxylation at the NBOMe part (B16, B23, B28, B30, B31 and C19, C25, C27, C33, C35). At the NBOMe moiety, bis-hydroxylation led to the fragment ion of m/z 153.0552 (B33, B34 and C34, C36) and O-demethylation to fragment ion of m/z 107.0497 (B7, B9,  B10, B11, B15, B19, B21 and C8, C9, C11, C12, C14, C18, C21, C23,  C26 ). The fragment ion of m/z 107.0497 could also be found for the NBOMe mono-hydroxylated (B16, B23, B28, B31 and C19, C25, C27, C33) or NBOMe bis-hydroxylated (B34 and C34, C35, C36) metabolites, but consistently in combination with the fragment ions of m/z 137.0603 or m/z 153.0552 as mentioned above. Therefore, the absence of the fragment ions of m/z 137.0603 and 153.0552 indicated O-demethylation at the NBOMe part. O-Demethylation combined with mono-hydroxylation led to fragment ion of m/z 123.0446 (B17, B18, B24, B25 and C20, C22, C28, C29). As mentioned above, all N-demethoxybenzyl metabolites were identified based on the 2C part fragmentation patterns (B2-B6 and C2-C7).
In summary, the fragmentation patterns of both NBOMes corresponded to those of 25I-NBOMe. Some compound-related characteristics were found for the bromo and chloro analogues as already described for 25I-NBOMe. All metabolites, which were Odemethylated at the NBOMe part (m/z 107.0497), showed higher abundances for fragment ions representing the 2C part probably due to a hydrogen bond between the nitrogen and the hydroxy group resulting from O-demethylation at the NBOMe part [25] . In addition, for these metabolites, the corresponding 2C fragment ion carrying the nitrogen was represented by the 2C primary amine instead of the 2C iminium ion found for the parent compounds or metabolites, which were not O-demethylated at the NBOMe part.
It was not possible in this study to identify the demethylated position of the methoxy group (2 -or 5 -position) or the position at which the NBOMe part was hydroxylated. Nevertheless, Wohlfarth et al. [26] synthesized six potential 25C-NBOMe metabolites (2 -and 5 -O-demethyl-25C-NBOMe and 3-/4-/5-and 6-hydroxy-25C-NBOMe) to confirm the exact position of the metabolic reaction. They observed that both in vivo samples (mouse and human urine) showed prevalence for O-demethylation at the 5 -position. Furthermore, they observed that the most intense signal for a mono-hydroxylated metabolite was detected for 5-hydroxy-25C-NBOMe in human urine as well as in mouse urine. In general, Wohlfarth et al. described the same main metabolic steps compared to the present study and 25I-NBOMe [25] . In accordance, Leth-Petersen et al. [28] described that the main metabolic step of 25B-NBOMe was also the 5 -O-demethylation in humans and pigs.
Identification of 25B-NBOMe and 25C-NBOMe and their phase I metabolites via HR-MS/MS fragmentation
The phase II metabolite formation and fragmentation patterns were very similar for both compounds and comparable with those described for 25I-NBOMe. For both compounds, the precursor masses and the most abundant fragment ions formed from unmodified or modified NBOMe part were used to identify the corresponding phase II metabolites. 2C fragment ions were used to confirm the predicted metabolites.
Overall, 31 phase II metabolites could be identified for 25B-NBOMe and 33 for 25C-NBOMe. A list of all phase II metabolites is given in Tables S3 and S4 in the electronic Supplementary data. All glucuronides eliminated glucuronic acid (−176.0321 u) and all sulfates sulfuric acid (−79.9568 u). Thus, the rest of the spectra of phase II conjugates was in accordance with the spectrum of the corresponding phase I metabolite. Also, for some phase II metabolites, fragment ions formed by conjugated partial structures could be used to elucidate the position of the conjugation.
As already described for 2C derivatives [37] and 25I-NBOMe the metabolites formed after N-demethoxybenzylation could further be conjugated by acetylation, glucuronidation, sulfation, or even combinations of them. Furthermore, in accordance to 25I-NBOMe, an O,O-bis-demethylation of the 2C part led to a hydroquinone partial structure, which could further be conjugated with glutathione (GSH). The degradation products of GSH conjugated metabolites could be found for both compounds. Also the described conjugation catalyzed by catechol-O-methyl-transferase (COMT) could be found for both NBOMes forming O-methyl metabolites (B33ME and C24ME, C36ME), after bis-hydroxylation at the NBOMe part (m/z 167.0708) producing a catecholic partial structure.
Initial CYP activity screening
For identification of the CYPs catalyzing the initial metabolic steps, the ten most abundant human hepatic CYPs were incubated under conditions allowing a statement on the general involvement of a particular CYP enzyme. It should be kept in mind that these qualitative data did not reflect a quantitative contribution of Table 1 General involvement of the CYP isoenzymes on the formation of the given 25B-NBOMe metabolites, numbering according to Table S1 . Table 2 General involvement of the CYP isoenzymes on the formation of the given 25C-NBOMe metabolites, numbering according to Table S2 . Tables  S2 and S4. a CYP to the hepatic clearance that would require the collection of enzyme kinetic data [38] , which was beyond the scope of this study. As summarized in Tables 1 and 2, CYP2C9 and CYP2C219 were involved in O-demethylation for both, 25B-NBOMe and 25C-NBOMe, respectively, CYP1A2 and CYP3A4 in hydroxylation, and CYP3A4 in N-demethoxybenzylation.
Proposed metabolic pathways
According to the 25B-NBOMe metabolites identified in human and rat urine after cleavage of conjugates and 25C-NBOMe metabolites identified in rat urine after cleavage of conjugates (Tables S1  and S2 ), the following metabolic pathways, depicted in Figs. 1 and 2 , could be proposed.
As expected, both compounds underwent the same main metabolic steps. O-Demethylation led to the most abundant peaks in human and rat urine followed by O-bis-demethylation and/or by O-demethylation plus hydroxylation. N-Demethoxybenzylation led to only small peaks in both species. However, the relative abundance of the different metabolites varied between the species, but it should also be kept in mind that the rat urines were pooled over 24 h and the human urine was collected at an unknown time after administration of an unknown dose. Finally, the relation of the metabolites may vary over the time of excretion.
For both derivatives, the following phase I pathways could be found: mono-demethylation (B13-B15 and C16-C18), bisdemethylation (B8-B10 and C10-C12), tris-demethylation (B7 and C8) of the methoxy groups, mono-and bis-hydroxylation (B29-B32, B34, B35, and C31-C33, C35, C36), N-demethoxybenzylation (B6 and C5), and combinations of mono-hydroxylation with monodemethylation (B22-B25 and C26-C29), and bis-demethylation (B16-B19 and C19-C23) as well as bis-hydroxylation with mono-demethylation (B33 and C34), and N-demethoxybenzylation with mono-demethylation (B3, B4 and C2, C3) followed by oxidative deamination (B2) and oxidation to the corresponding carboxylic acid (B5 and C4). In addition, for 25C-NBOMe also N-demethoxybenzylation with mono-hydroxylation (C7), and oxidation forming an amide structure (C6) could be predicted. Also, dehydro metabolites (B20 and C24) were found for both compounds. The presence of this metabolic step was already described for 25I-NBOMe [25] .
Nielsen et al. [39] described dehydrogenation as a CYP-catalyzed reaction. The resulting double bond was located at the 2C moiety and not between the nitrogen and the ␣-carbon of the 2C moiety as confirmed with reference standard of the 25I-NBOMe imine. These compounds could further be metabolized by mono-demethylation (B11, B12 and C13-C15), bis-demethylation (C9), hydroxylation (B26-B28 and C30), and combination of mono-demethylation and hydroxylation (B21 and C25). However, the possibility could not be excluded that the dehydro compound could also be formed by artificial dehydration of the corresponding hydroxy metabolite. If hydroxylation took place at the ␣-position to the nitrogen forming an unstable hemiaminal, then this metabolite could further eliminate water under the ESI conditions described above. In summary, the metabolic pathways for 25B-NBOMe and 25C-NBOMe corresponded to those described for 25I-NBOMe, i.e. showing the same main phase I metabolism reactions.
The following phase II pathways could be proposed for humans and/or rats as given in Tables S3 and S4 and Figs. 1 and 2: sulfation (S) glucuronidation (G) and/or of the O-demethyl metabolites (B13/14S, B15S, B13G-B15G and C16/17S, C18S, C16G-C18G), of the O,O-bis-demethyl metabolites (B8S, B9/10S, B8G, B9/10G and C10S-C12S, C10G-C12G), of O,O,O-tris-demethyl metabolite (B7S, B7G and C8S, C8G), of the O-demethyl-hydroxy metabolites (B22S, B24/25S, B22G, B23, B24/25G and C22S, C27S, C28/29S), of the O,Obis-demethyl-hydroxy metabolites (B16S, B17/18S, B16G, B19G and C20S, C19G-C22G), and of the hydroxy metabolites (B30G, B31G and C31/32G, C33G). Glutathione (GSH) conjugation could be proposed for the O,O-bis-demethyl metabolite isomer 1 (B8-GSH-1, B8-GSH-2 and C10-GSH-1, C10-GSH-2), N-acetylation (AC) for the N-demethoxybenzyl-O-demethyl metabolites (B3, B4 and C2, C3) followed by further sulfation and/or glucuronidation (B3AC+S, B4AC+S, B3/4AC+G and C3/4AC+S, C2/3AC+G), and O-methylation (ME) of the bis-hydroxy metabolite (C36ME) and the O-demethylbis-hydroxy metabolites (B33ME and C34ME). In summary, all phase II pathways could be proposed for both species except for glutathione conjugation, which was observed only in rats after administration of the high dose.
Comparison of metabolite formation in vitro and in vivo and in different species
In contrast to the development of new therapeutics drug, pharmacokinetic data are not routinely collected for NPS before Table 3 25B-NBOMe phase I and II metabolites detected in rat (RU) and human (HU) urine compared to those detected in human liver microsome (HLM) incubation published by Boumrah et al. [27] and in HLM and porcine liver microsome (PLM) incubations published by Leth-Petersen et al. [28] . Numbering according to Tables S1 and S3, * = metabolite only described in references [27, 28] .
No.
Metabolite RU HU HLM [27] HLM [28] PLM [28] B1 25B-NBOMe emergence on the market. For ethical reasons, controlled human studies are not possible. Therefore, animal studies under controlled conditions are common in combination with human in vivo assays as described e.g. in refs. [25, 26] . Both data can be confirmed by authentic human samples of e.g. intoxication cases. For development of urine screening approaches, it is important to know the possible target. Thus, any metabolites identified first in animal urine can become the main target in human urine considering e.g. inter-species and/or genetic variations in drug metabolism and transport. For this reason, Tables 3 and 4 list the phase I and II metabolites identified in this study compared to those detected in human liver microsomes (HLM) incubation, porcine liver microsomes (PLM) incubation, mouse urine (MU), authentic human urines (HU), or human hepatocyte (HP) incubation. Differences could be explained by species differences, higher doses, and/or different sampling time after administration.
25B-NBOMe
Boumrah et al. [27] described 21 phase I and II metabolites of 25B-NBOMe identified only in vitro after incubation with HLM and cofactors for CYPs and glucuronyl transferases. Leth-Petersen et al. [28] compared formation of phase I metabolites in HLM and PLM incubations. In the present study, 35 phase I and 31 phase II metabolites have been identified in human and rat urine. According to Table 3 , in both urine samples, various metabolites could be identified not described by Boumrah et al. or Leth-Petersen et al. Most of them were isomers of metabolites formed by combined metabolic reactions such as mono-and bis-O-demethylation with hydroxylation or O-demethylation with N-dealkylation. Species differences occurred for the hydroxylation step because rats seemed to prefer hydroxylation at the 2C part whereas human biotransformation might result in preferential hydroxylation at the NBOMe part. Concerning phase II metabolism, Boumrah et al. investigated only the glucuronide formation. In the present study, sulfation, Nacetylation, and O-methylation were found in rat and human urine as further reactions. In addition, rats showed GSH conjugation and combinations of N-acetylation with sulfation or glucuronidation.
In contrast, the N-glucuronide of the parent compound detected in HLM could not be found in the human or rat urine. Table 4 summarizes the data obtained in rat urine and those in human hepatocytes and urines of humans and mice [26] . Concerning phase I metabolism, most metabolites were common for all species while the highest number was found in the rat urine probably due to the high dosage, urine collection time, sample preparations, and/or chromatographic separation. Some metabolites were only detected in rat urine such as the combined N-dealkylated and O-demethylated metabolites or various isomers of O,O-bis-demethyl-hydroxy metabolites. Wohlfarth et al. [26] described N-oxidation and carbonylation in the hepatocyte incubation although it was not clear why this could not be found in their human and mice urine. As already described for 25B-NBOMe, rats seemed to preferentially hydroxylated at the 2C part and humans at the NBOMe part. Most phase II pathways could be proposed for all three species with the exception of O-acetylation, N-acetylation, GSH conjugation, and O-methylation. Again, the highest number of metabolites was identified in rat urine probably due to the reasons described above. 
25C-NBOMe
GC-MS SUSA
Unfortunately, 25B-NBOMe and 25C-NBOMe and/or their metabolites could not be detected in rat urine after low dose administration (0.1 mg/kg BW). However, 25B-NBOMe and metabolites (Table 5 ) could be detected in the human urine sample by GC-MS SUSA. The compound ingested by the user was believed to be 2C-B, which typically requires a ten-fold higher dose compared to 25B-NBOMe [7] . Therefore, for acute and/or severe poisonings with NBOMes an intake could also be detected by GC-MS SUSA. 25C-NBOMe could only be detected after the high dose, enzymatic Table 4 25C-NBOMe phase I and II metabolites detected in rat (RU) urine compared to those in authentic human urines (HU), mouse urine (MU) and human hepatocyte (HP) incubation as published by Wohlfarth et al. [26] . Numbering according to Tables S2 and S4, * = metabolite only described in reference [26] .
No.
Metabolite RU HU [26] MU [26] HP [26] C1 25C-NBOMe Table 5 25B-NBOMe and its metabolites, molecular mass, five most abundant EI-GC-MS fragment ions, retention indices (RI), and detectability in rat urine (RU) or human urine (HU) by GC-MS SUSA. The numbers correspond to those of 
